These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26348357)

  • 21. CTLA-4 blockade and the renaissance of cancer immunotherapy.
    Mocellin S; Nitti D
    Biochim Biophys Acta; 2013 Dec; 1836(2):187-96. PubMed ID: 23748107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure.
    Zhao Q; Xia N
    Sci China Life Sci; 2016 Nov; 59(11):1198-1201. PubMed ID: 27785725
    [No Abstract]   [Full Text] [Related]  

  • 24. Hearing restoration: Graeme Clark, Ingeborg Hochmair, and Blake Wilson receive the 2013 Lasker~DeBakey Clinical Medical Research Award.
    Williams C
    J Clin Invest; 2013 Oct; 123(10):4102-6. PubMed ID: 24091320
    [No Abstract]   [Full Text] [Related]  

  • 25. [Immuno-oncology--silver bullets or mass destruction weapons?].
    Utriainen M; Rämet M
    Duodecim; 2016; 132(8):721-8. PubMed ID: 27244931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
    Pico de Coaña Y; Choudhury A; Kiessling R
    Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of Cell-Free Fetal DNA in Maternal Blood and Development of Noninvasive Prenatal Testing: 2022 Lasker-DeBakey Clinical Medical Research Award.
    Lo YMD
    JAMA; 2022 Oct; 328(13):1293-1294. PubMed ID: 36170057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Checkpoint Blockade in Cancer Therapy.
    Postow MA; Callahan MK; Wolchok JD
    J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Lasker-DeBakey Clinical Medical Research Award.
    Samy RN
    Curr Opin Otolaryngol Head Neck Surg; 2014 Oct; 22(5):343. PubMed ID: 25101944
    [No Abstract]   [Full Text] [Related]  

  • 30. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoint modulation: rational design of combination strategies.
    Zamarin D; Postow MA
    Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Lasker Awards--Recognizing and Highlighting Oncology Research.
    Disis ML
    JAMA; 2015 Sep; 314(11):1123-4. PubMed ID: 26372574
    [No Abstract]   [Full Text] [Related]  

  • 33. Trio of Scientists Wins Lasker Award.
    Cancer Discov; 2016 Nov; 6(11):1200-1201. PubMed ID: 27707763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer immunotherapy shows promise in multiple tumor types.
    Heger M
    Nat Med; 2012 Jul; 18(7):993. PubMed ID: 22772534
    [No Abstract]   [Full Text] [Related]  

  • 35. Role of the crosstalk between CTLA-4 and NKG2D in the development of anti-CTLA-4 treatment strategies.
    Demaria S; Dustin ML
    Immunotherapy; 2013 Feb; 5(2):109-12. PubMed ID: 23413900
    [No Abstract]   [Full Text] [Related]  

  • 36. Breakthrough of the year 2013. Cancer immunotherapy.
    Couzin-Frankel J
    Science; 2013 Dec; 342(6165):1432-3. PubMed ID: 24357284
    [No Abstract]   [Full Text] [Related]  

  • 37. Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.
    Condomines M; Arnason J; Benjamin R; Gunset G; Plotkin J; Sadelain M
    PLoS One; 2015; 10(6):e0130518. PubMed ID: 26110267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An introduction to tumour immunology.
    Keith J
    Mater Med Pol; 1984; 16(1):54-64. PubMed ID: 6394909
    [No Abstract]   [Full Text] [Related]  

  • 39. Women and non-white people among Lasker Award recipients from 1946 to 2022: cross sectional study.
    Jacobs JW; Bibb LA; Allen ES; Ward DC; Booth GS; Silver JK; Adkins BD
    BMJ; 2023 May; 381():e074968. PubMed ID: 37197781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic use of anti-CTLA-4 antibodies.
    Blank CU; Enk A
    Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.